Loading
The antibody-drug conjugates used in triple-negative breast cancer carry chemotherapy into the cancer but still cause chemotherapy-like effects: sacituzumab govitecan mainly low white cells and diarrhoea, datopotamab deruxtecan mouth soreness, eye problems and rarely lung inflammation, trastuzumab deruxtecan lung inflammation and sickness. Each has a threshold for ringing the 24-hour line.
Macmillan says sacituzumab govitecan is given on days 1 and 8 of a 21-day cycle, that it can cause severe diarrhoea, and to contact the hospital straight away on the 24-hour number for diarrhoea 4 or more times in a day, diarrhoea at night, or anti-diarrhoea drugs not working within 24 hours, as well as for a temperature above 37.5 C or below 36 C. Breast Cancer Now uses 3 or more times in 24 hours and says growth factor injections are sometimes recommended to protect white cells. The Datroway label requires eye examinations and lists keratitis; the Enhertu label carries a boxed warning for interstitial lung disease, and a pooled analysis found 15.4% of people on trastuzumab deruxtecan developed drug-related lung inflammation, most within the first year. This is orientation from public patient pages and guidelines, not advice for your case: your own team's instructions and 24-hour number come first.
Showing the molecule this term concerns: Sacituzumab govitecan.
Shares Neutropenia, Sacituzumab govitecan, Triple-negative breast cancer (TNBC).
Shares Interstitial lung disease (ILD) / pneumonitis, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Datopotamab deruxtecan, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Interstitial lung disease (ILD) / pneumonitis, Sacituzumab govitecan, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Sacituzumab govitecan, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Datopotamab deruxtecan, Sacituzumab govitecan, Trastuzumab deruxtecan, Triple-negative breast cancer (TNBC).
Shares Interstitial lung disease (ILD) / pneumonitis, Datopotamab deruxtecan, Trastuzumab deruxtecan.
Shares Sacituzumab govitecan, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).